TM
PACB icon

Thrax Management’s Pacific Biosciences PACB Stock Holding History

Thrax Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-410,876
Closed -$3.68M – 223
2016
Q3 		$3.68M Buy
+410,876
New +$3.43M 1.31% 20

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Thrax Management's PACB Position: Q4 2016 in Review

Thrax Management sold out of Pacific Biosciences (PACB) in Q4 2016, closing a stake of 410,876 shares — an estimated $3.68M sold.

Thrax Management first reported a position in PACB in Q3 2016 and held it in 1 quarter. The position peaked at $3.68M in Q3 2016. 115 funds tracked by Wall St. Rank hold PACB as of Q4 2016.

  • Thrax Management reported no remaining Pacific Biosciences position as of Q4 2016 after selling out during the quarter.
  • Thrax Management sold 410,876 Pacific Biosciences shares in Q4 2016, an estimated $3.68M.
  • Thrax Management first reported a position in Pacific Biosciences in Q3 2016 and held it in 1 quarter.
  • Thrax Management's Pacific Biosciences position peaked at $3.68M in Q3 2016.
  • 115 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2016.

Based on Thrax Management's 13F filing for Q4 2016, filed 16 Feb 2017.